QQQ   444.60 (+1.28%)
AAPL   178.63 (-1.17%)
MSFT   414.07 (+0.10%)
META   501.24 (+2.27%)
GOOGL   137.99 (-0.34%)
AMZN   178.03 (+0.72%)
TSLA   203.12 (+0.61%)
NVDA   818.42 (+3.45%)
NIO   5.82 (+1.22%)
AMD   200.43 (+4.10%)
BABA   74.71 (+0.92%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.43 (+5.32%)
CGC   3.27 (-0.61%)
GE   159.06 (+1.38%)
DIS   111.80 (+0.20%)
AMC   4.43 (+2.55%)
PFE   26.58 (+0.08%)
PYPL   60.63 (+0.48%)
XOM   105.82 (+1.24%)
QQQ   444.60 (+1.28%)
AAPL   178.63 (-1.17%)
MSFT   414.07 (+0.10%)
META   501.24 (+2.27%)
GOOGL   137.99 (-0.34%)
AMZN   178.03 (+0.72%)
TSLA   203.12 (+0.61%)
NVDA   818.42 (+3.45%)
NIO   5.82 (+1.22%)
AMD   200.43 (+4.10%)
BABA   74.71 (+0.92%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.43 (+5.32%)
CGC   3.27 (-0.61%)
GE   159.06 (+1.38%)
DIS   111.80 (+0.20%)
AMC   4.43 (+2.55%)
PFE   26.58 (+0.08%)
PYPL   60.63 (+0.48%)
XOM   105.82 (+1.24%)
QQQ   444.60 (+1.28%)
AAPL   178.63 (-1.17%)
MSFT   414.07 (+0.10%)
META   501.24 (+2.27%)
GOOGL   137.99 (-0.34%)
AMZN   178.03 (+0.72%)
TSLA   203.12 (+0.61%)
NVDA   818.42 (+3.45%)
NIO   5.82 (+1.22%)
AMD   200.43 (+4.10%)
BABA   74.71 (+0.92%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.43 (+5.32%)
CGC   3.27 (-0.61%)
GE   159.06 (+1.38%)
DIS   111.80 (+0.20%)
AMC   4.43 (+2.55%)
PFE   26.58 (+0.08%)
PYPL   60.63 (+0.48%)
XOM   105.82 (+1.24%)
QQQ   444.60 (+1.28%)
AAPL   178.63 (-1.17%)
MSFT   414.07 (+0.10%)
META   501.24 (+2.27%)
GOOGL   137.99 (-0.34%)
AMZN   178.03 (+0.72%)
TSLA   203.12 (+0.61%)
NVDA   818.42 (+3.45%)
NIO   5.82 (+1.22%)
AMD   200.43 (+4.10%)
BABA   74.71 (+0.92%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.43 (+5.32%)
CGC   3.27 (-0.61%)
GE   159.06 (+1.38%)
DIS   111.80 (+0.20%)
AMC   4.43 (+2.55%)
PFE   26.58 (+0.08%)
PYPL   60.63 (+0.48%)
XOM   105.82 (+1.24%)
NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

$24.45
+0.90 (+3.82%)
(As of 12:56 PM ET)
Today's Range
$23.46
$24.48
50-Day Range
$22.18
$29.10
52-Week Range
$19.52
$30.52
Volume
239,550 shs
Average Volume
574,985 shs
Market Capitalization
$1.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Veracyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
23.2% Upside
$30.00 Price Target
Short Interest
Healthy
3.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.02
Upright™ Environmental Score
News Sentiment
0.45mentions of Veracyte in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.29) to ($0.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

250th out of 957 stocks

Medical Laboratories Industry

9th out of 21 stocks


VCYT stock logo

About Veracyte Stock (NASDAQ:VCYT)

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock Price History

VCYT Stock News Headlines

Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Veracyte (NASDAQ:VCYT) Shares Down 7.3%
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Veracyte (NASDAQ:VCYT) Rating Reiterated by William Blair
Recap: Veracyte Q4 Earnings
Veracyte (VCYT) Set to Announce Quarterly Earnings on Thursday
VCYT Mar 2024 35.000 put
VCYT Mar 2024 20.000 put
Veracyte Completes Acquisition of C2i Genomics
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
3/01/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:VCYT
Employees
787
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$34.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+24.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-74,400,000.00
Pretax Margin
-14.45%

Debt

Sales & Book Value

Annual Sales
$361.05 million
Book Value
$14.98 per share

Miscellaneous

Free Float
71,141,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
1.68

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 54)
    CEO & Director
    Comp: $1.25M
  • Ms. Rebecca ChambersMs. Rebecca Chambers (Age 46)
    Executive VP & CFO
    Comp: $772.41k
  • Ms. Annie McGuire (Age 43)
    Executive VP, General Counsel & Chief People Officer
    Comp: $633.65k
  • Mr. Jonathan Wygant (Age 53)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Senior VP & Chief Information Officer
  • Dr. Phillip G. Febbo M.D. (Age 58)
    Chief Scientific & Medical Officer
  • Ms. Karen Possemato
    Senior Vice President of Corporate Marketing, Communications & Commercial Operations
  • Mr. Robert Brainin (Age 53)
    Executive VP & Chief Business Officer
  • Dr. John Leite Ph.D.
    Chief Commercial Officer for CLIA Business
  • Ms. Corinne Danan
    Senior VP and GM of Biopharma & IVD Services














VCYT Stock Analysis - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price target for 2024?

5 brokers have issued 1 year price objectives for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2024?

Veracyte's stock was trading at $27.51 at the beginning of the year. Since then, VCYT shares have decreased by 11.5% and is now trading at $24.36.
View the best growth stocks for 2024 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The biotechnology company earned $90.32 million during the quarter, compared to analysts' expectations of $83.05 million. Veracyte had a negative trailing twelve-month return on equity of 2.01% and a negative net margin of 20.61%. The business's revenue for the quarter was up 24.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (10.48%), Vanguard Group Inc. (9.75%), Dimensional Fund Advisors LP (4.62%), Artisan Partners Limited Partnership (4.41%), Sumitomo Mitsui Trust Holdings Inc. (4.25%) and Nikko Asset Management Americas Inc. (4.25%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
This page (NASDAQ:VCYT) was last updated on 3/1/2024 by MarketBeat.com Staff